Illumina (ILMN)

• Market cap: $21.2B
• 1 day: -1.20%
• 5 days: -1.29%
• 1 month: -7.92%
• 3 months: 2.48%
• 6 months: 26.68%
• Year to date: -2.88%
• 1 year: -2.88%
• 5 years: -59.27%
• 10 years: -28.26%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Employees: 9,300

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

56% more funds holding in top 10

Funds holding in top 10: 9 [Q2] → 14 (+5) [Q3]

28% more first-time investments, than exits

New positions opened: 138 | Existing positions closed: 108

23% more capital invested

Capital invested by funds: $14.9B [Q2] → $18.4B (+$3.48B) [Q3]

4% more funds holding

Funds holding: 756 [Q2] → 786 (+30) [Q3]

1% more repeat investments, than reductions

Existing positions increased: 273 | Existing positions reduced: 269

1.12% less ownership

Funds ownership: 89.82% [Q2] → 88.7% (-1.12%) [Q3]

13% less call options, than puts

Call options by funds: $174M | Put options by funds: $199M

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $139 4% upside
• Avg. target: $170 27% upside
• High target: $254 90% upside

13 analyst ratings

• positive: 6 46%
• neutral: 7 54%
• negative: 0 0%

Citigroup Patrick Donnelly 43% 1-year accuracy 13 / 30 met price target	23% upside $165	Neutral Downgraded	11 Dec 2024
Morgan Stanley Tejas Savant 33% 1-year accuracy 4 / 12 met price target	17% upside $156	Equal-Weight Reinstated	12 Nov 2024
Stephens & Co. Mason Carrico 72% 1-year accuracy 13 / 18 met price target	38% upside $184	Overweight Maintained	12 Nov 2024
Piper Sandler David Westenberg 69% 1-year accuracy 27 / 39 met price target	38% upside $185	Overweight Maintained	11 Nov 2024
Baird Catherine Ramsey 83% 1-year accuracy 10 / 12 met price target	4% upside $139	Neutral Maintained	6 Nov 2024